[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
3. Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM: Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood; 2001 Jan 15;97(2):528-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma.
  • LL2, an anti-CD22 monoclonal antibody against B-cell lymphoma, was covalently linked to the amphibian ribonuclease, onconase, a member of the pancreatic RNase A superfamily.
  • LL2 increased in vitro potency (10 000-fold) and specificity against human Daudi Burkitt lymphoma cells while decreasing systemic toxicity of onconase.
  • These favorable in vitro properties translated to significant antitumor activity against disseminated Daudi lymphoma in mice with severe combined immunodeficiency disease.
  • In mice inoculated with tumor cells intraperitoneally (ip), LL2-onconase (100 microg 5 times ip every day) increased the life span of animals with minimal disease 200%.
  • The life span of mice with advanced disseminated Daudi lymphoma (tumor cells inoculated intravenously) was increased 135%.
  • Because both onconase and LL2 are in clinical trials as cancer therapeutics, the covalently linked agents should be considered for treatment of non-Hodgkin lymphoma.
  • [MeSH-minor] Animals. Antigens, CD / immunology. Antigens, Differentiation, B-Lymphocyte / immunology. Cell Death / drug effects. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Drug Stability. Female. Humans. Immunotoxins / pharmacology. Immunotoxins / therapeutic use. Immunotoxins / toxicity. Kinetics. Lymphoma, Non-Hodgkin / drug therapy. Mice. Mice, Inbred BALB C. Mice, SCID. Models, Animal. Neoplasm Transplantation. Pancreas / enzymology. Sialic Acid Binding Ig-like Lectin 2. Survival Rate. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11154233.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA39841; United States / NCI NIH HHS / CO / N01-CO-56000
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antineoplastic Agents; 0 / CD22 protein, human; 0 / Cd22 protein, mouse; 0 / Cell Adhesion Molecules; 0 / Immunotoxins; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / bectumomab; EC 3.1.- / Ribonucleases; EC 3.1.- / ranpirnase
  •  go-up   go-down


Advertisement
4. Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C, Kim KM, Nesterova A, Anderson M, McEarchern JA, Law CL, Smith LM: Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75. Br J Cancer; 2010 Aug 24;103(5):676-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.
  • BACKGROUND: CD70 is an ideal target for antibody-based therapies because of its aberrant high expression in renal carcinomas and non-Hodgkin lymphomas and its highly restricted expression in normal tissues.
  • The expression profiling of CD70 in carcinomas has been limited because of the lack of a CD70-specific reagent that works in formalin-fixed paraffin-embedded (FFPE) tissues.
  • METHODS: We generated murine monoclonal antibodies (mAbs) specific for CD70 and validated their specificity by western blot analysis and developed a protocol for immunohistochemistry on FFPE tissues.
  • CD70+ tumour cell lines were used for testing the anti-tumour activity of the anti-CD70 antibody-drug conjugate, SGN-75.
  • RESULTS: We report novel detection of CD70 expression in multiple cancers including pancreatic (25%), larynx/pharynx (22%), melanoma (16%), ovarian (15%), lung (10%), and colon (9%).
  • Our results show that pancreatic and ovarian tumour cell lines, which express high levels of endogenous or transfected CD70, are sensitive to the anti-tumour activity of SGN-75 in vitro and in vivo.
  • CONCLUSION: Development of murine mAbs for robust and extensive screening of FFPE samples coupled with the detection of anti-tumour activity in novel indications provide rationale for expanding the application of SGN-75 for the treatment of multiple CD70 expressing cancers.
  • [MeSH-major] Aminobenzoates / administration & dosage. Antigens, CD70 / immunology. Immunoconjugates / therapeutic use. Oligopeptides / administration & dosage. Ovarian Neoplasms / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Cell Line, Tumor. Drug Delivery Systems. Drug Screening Assays, Antitumor. Female. Humans. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7763-72 [19047103.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Curr Opin Chem Biol. 2009 Jun;13(3):235-44 [19414278.001]
  • [Cites] Am J Pathol. 2009 Aug;175(2):636-48 [19608876.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Sep;330(3):932-8 [19498104.001]
  • [Cites] Gynecol Oncol. 2009 Dec;115(3):430-7 [19800108.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):742-6 [10800994.001]
  • [Cites] Nat Immunol. 2000 Nov;1(5):433-40 [11062504.001]
  • [Cites] Immunity. 2001 Nov;15(5):801-12 [11728341.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2592-9 [11980654.001]
  • [Cites] Nat Immunol. 2003 Jan;4(1):49-54 [12469117.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7432-41 [15187121.001]
  • [Cites] Histopathology. 2004 Sep;45(3):226-36 [15330800.001]
  • [Cites] Cell. 1993 May 7;73(3):447-56 [8387892.001]
  • [Cites] J Immunol. 1994 Feb 15;152(4):1756-61 [8120384.001]
  • [Cites] J Immunol. 1994 Feb 15;152(4):1762-73 [8120385.001]
  • [Cites] Int Immunol. 1994 Mar;6(3):477-80 [8186199.001]
  • [Cites] J Immunol. 1995 Mar 15;154(6):2612-23 [7876536.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3556-65 [7540066.001]
  • [Cites] Am J Pathol. 1995 Oct;147(4):1152-60 [7573360.001]
  • [Cites] J Pathol. 1996 May;179(1):54-9 [8691346.001]
  • [Cites] Eur J Immunol. 1996 Dec;26(12):2964-71 [8977292.001]
  • [Cites] J Immunol. 1997 Sep 15;159(6):2652-7 [9300684.001]
  • [Cites] Blood. 1998 Jan 1;91(1):173-80 [9414282.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):491-503 [10460611.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):710-7 [15634890.001]
  • [Cites] J Urol. 2005 Jun;173(6):2150-3 [15879877.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1794-801 [16043348.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2328-37 [16489038.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):933-8 [17132225.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1185-92 [17038522.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Aug;7 Suppl 5:S199-206 [17877845.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6171-80 [18809969.001]
  • (PMID = 20664585.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminobenzoates; 0 / Antibodies, Monoclonal; 0 / Antigens, CD70; 0 / Immunoconjugates; 0 / Oligopeptides; 0 / auristatin
  • [Other-IDs] NLM/ PMC2938259
  •  go-up   go-down


5. Grimison PS, Chin MT, Harrison ML, Goldstein D: Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four cases. BMC Cancer; 2006;6:117
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four cases.
  • BACKGROUND: Primary pancreatic lymphomas (PPL) are rare tumours of the pancreas.
  • Symptoms, imaging and tumour markers can mimic pancreatic adenocarcinoma, but they are much more amenable to treatment.
  • Treatment for PPL remains controversial, particularly the role of surgical resection.
  • METHODS: Four cases of primary pancreatic lymphoma were identified at Prince of Wales Hospital, Sydney, Australia.
  • All patients were treated with chemotherapy and radiotherapy, and two of four patients received rituximab.
  • Outcomes in our series and other series of chemotherapy and radiotherapy compared favourably to surgical series.
  • CONCLUSION: Biopsy of all pancreatic masses is essential, to exclude potentially curable conditions such as PPL, and can be performed without laparotomy.
  • Combined multimodality treatment, utilising chemotherapy and radiotherapy, without surgical resection is advocated but a cooperative prospective study would lead to further improvement in treatment outcomes.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Biopsy. Combined Modality Therapy. Humans. Male. Middle Aged. Pancreas / pathology. Retrospective Studies. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreatology. 2003;3(5):359-65; discussion 365-6 [14526144.001]
  • [Cites] J Clin Epidemiol. 2005 Dec;58(12):1227-32 [16291466.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1086-90 [15205203.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):28-37 [15213615.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):44-50 [15213617.001]
  • [Cites] JOP. 2004 Jul;5(4):247-52 [15254358.001]
  • [Cites] Dig Dis. 2004;22(1):26-31 [15292692.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Cancer. 2004 Aug 25;102(4):203-6 [15368310.001]
  • [Cites] Cancer. 2004 Aug 25;102(4):239-46 [15368316.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):313-8 [15468134.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] Ann Surg. 1976 Dec;184(6):705-8 [793544.001]
  • [Cites] Cancer Treat Rep. 1977 Sep;61(6):1023-7 [902260.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Gastrointest Radiol. 1986;11(1):41-3 [3943677.001]
  • [Cites] Am J Surg. 1987 Jul;154(1):134-6 [3300394.001]
  • [Cites] Ann Surg. 1989 Jan;209(1):25-30 [2910212.001]
  • [Cites] Arch Surg. 1989 Nov;124(11):1287-9 [2818182.001]
  • [Cites] Lancet. 1992 Dec 19-26;340(8834-8835):1488-92 [1281903.001]
  • [Cites] Endoscopy. 1993 Mar;25(3):207-12 [8519239.001]
  • [Cites] Am Surg. 1993 Aug;59(8):513-8 [8338282.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):860-7 [10673529.001]
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):319-30 [10703858.001]
  • [Cites] Eur J Surg Oncol. 2000 Aug;26(5):474-9 [11016469.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):796-9 [11875013.001]
  • [Cites] Hepatogastroenterology. 2002 Jul-Aug;49(46):944-6 [12143249.001]
  • [Cites] Radiology. 2002 Oct;225(1):27-34 [12354980.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2740-6 [12860953.001]
  • [Cites] Radiographics. 2003 Sep-Oct;23(5):1117-31 [12975504.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] J Clin Gastroenterol. 1996 Sep;23(2):109-12 [8877636.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):209-13 [9135490.001]
  • [Cites] Gastroenterology. 1997 Jun;112(6):2104-7 [9178704.001]
  • [Cites] Surgery. 1998 Apr;123(4):382-90 [9551063.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):315-21 [15386314.001]
  • [Cites] Acta Gastroenterol Belg. 2004 Jul-Sep;67(3):294-300 [15587339.001]
  • [Cites] Haematologica. 2005 Feb;90(2):ECR09 [15713583.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1250-2 [15788502.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7050-9 [16129843.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1751-7 [14630680.001]
  • (PMID = 16674812.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 49
  • [Other-IDs] NLM/ PMC1475874
  •  go-up   go-down


6. Basu A, Patil N, Mohindra P, Zade B, Gujral S, Muckaden MA, Laskar S: Isolated non-Hodgkin's lymphoma of the pancreas: case report and review of literature. J Cancer Res Ther; 2007 Oct-Dec;3(4):236-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated non-Hodgkin's lymphoma of the pancreas: case report and review of literature.
  • BACKGROUND: Isolated primary pancreatic lymphoma (PPL) is a rare extra-lymphatic non-Hodgkin's lymphoma comprising less than 1% of all extra-lymphatic lymphomas.
  • It is difficult to diagnose; the vague presenting symptoms and nonspecific laboratory/radiological findings make it difficult to differentiate the condition from pancreatic adenocarcinoma.
  • Histopathological examination is of paramount importance to conclusively establish the diagnosis since the treatment involves lymphoma protocols, and prognosis and survival in PPL are considerably superior to that in adenocarcinoma pancreas.
  • RESULT: The patient was treated with multi-agent combination chemotherapy followed by radiotherapy.
  • CONCLUSION: An exceedingly rare entity, isolated PPLs need to be differentiated from pancreatic adenocarcinomas by histopathological evaluation since management is on the lines of other extralymphatic lymphomas and prognosis is significantly better.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Humans. Male. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18270400.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


7. Arcari A, Anselmi E, Bernuzzi P, Bertè R, Lazzaro A, Moroni CF, Trabacchi E, Vallisa D, Vercelli A, Cavanna L: Primary pancreatic lymphoma. Report of five cases. Haematologica; 2005 Feb;90(2):ECR09
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic lymphoma. Report of five cases.
  • Primary pancreatic lymphoma (PPL) is a very rare disease.
  • Imaging techniques showed a mass of the pancreatic head in all cases.
  • The histological diagnosis (3 diffuse-large cell non-Hodgkin's lymphoma and 2 lymphoplasmacytic lymphoma/immunocytoma) was made by ultrasound-guided fine needle aspiration biopsy and tissue core fine-needle biopsy in three patients and by surgery in the remaining two patients.
  • The three patients diagnosed by percutaneous biopsy were treated with chemotherapy as front-line therapy and two of them received also local radiotherapy; one of these patients is still alive in complete remission at 69 months, one died of an unrelated disease at 67 months and one died of lymphoma relapse at 88 months.
  • Two patients underwent pancreaticoduodenectomy plus adjuvant chemotherapy; one of them died of recurrent cholangitis 8 months after surgery while the other one is still alive in complete remission after 160 months.
  • 1) imaging techniques can suggest the suspicion of PPL but are unable to distinguish PPL from pancreatic adenocarcinoma;.
  • 2) histological diagnosis can be easily obtained by percutaneous US-guided tissue core biopsy;.
  • 3) surgery can be avoided both for diagnosis and therapy but the treatment of choice of PPL may only be evaluated on a larger series of patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy. Biopsy, Needle. Female. Humans. Male. Middle Aged. Recurrence. Remission Induction. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15713583.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Aftandilian CC, Friedmann AM: Burkitt lymphoma with pancreatic involvement. J Pediatr Hematol Oncol; 2010 Nov;32(8):e338-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma with pancreatic involvement.
  • Intraoperative biopsies confirmed Burkitt lymphoma.
  • Further imaging and biopsy revealed pancreatic involvement.
  • He was treated with multiagent chemotherapy.
  • Review of the literature demonstrates other cases of non-Hodgkin lymphoma with pancreatic involvement with good outcomes.
  • Pancreatic involvement is a relatively rare occurrence in childhood lymphoma.
  • [MeSH-major] Burkitt Lymphoma / pathology. Oropharyngeal Neoplasms / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Humans. Male. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20930650.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Schiefke I, Tröltzsch M, Keim V: [Pitfalls in diagnosis of non-Hodgkin-lymphoma of the pancreas]. Ultraschall Med; 2002 Dec;23(6):407-10
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pitfalls in diagnosis of non-Hodgkin-lymphoma of the pancreas].
  • [Transliterated title] Diagnostik eines isolierten Non-Hodgkin-Lymphoms im Pankreas--Was tun bei diskrepanten Befunden in der Computertomographie und im Ultraschall?
  • Both ultrasound and endoscopic ultrasound revealed a lesion of low echogenicity in the pancreatic head without indication of hepatic lesions, enlarged lymph nodes or vascular infiltration.
  • An computed tomography (CT) did not show the lesion in the pancreas.
  • The biopsy specimen revealed a diffuse large cell Non-Hodgkin-Lymphoma.
  • This case report illustrates, how simple ultrasound studies can detect lesions not seen in more expensive, complex, and time consuming imaging techniques like CT.
  • The patient underwent a postoperative chemotherapy and is currently well.
  • [MeSH-major] Lymphoma, Non-Hodgkin / ultrasonography. Pancreatic Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Female. Humans. Reproducibility of Results. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12514759.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Battula N, Srinivasan P, Prachalias A, Rela M, Heaton N: Primary pancreatic lymphoma: diagnostic and therapeutic dilemma. Pancreas; 2006 Aug;33(2):192-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic lymphoma: diagnostic and therapeutic dilemma.
  • OBJECTIVES: Non-Hodgkin lymphoma predominantly involving the pancreas is a rare tumor and accounts for less than 0.7% of all pancreatic malignancies and 1% of extranodal lymphomas.
  • Diagnosis of primary pancreatic lymphoma can be difficult because it may mimic carcinoma.
  • METHODS: A PubMed search was conducted using the following terms: primary pancreatic lymphoma and non-Hodgkin lymphoma of the pancreas.
  • RESULTS: A total of 89 reported cases of pancreatic lymphoma between 1951 and 2005 were reviewed.
  • An accurate preoperative diagnosis of primary pancreatic lymphoma is not always possible.
  • A complete response rate of 100% and a long-term survival rate of 94% have been reported with surgery and adjuvant chemotherapy when compared with a 5-year survival rate of less than 50% and an overall 3-year disease-free survival rate of 44% with current chemotherapy, radiotherapy, or combined methods.
  • CONCLUSION: Pancreaticoduodenectomy may have a therapeutic role in association with chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / surgery. Lymphoma, Non-Hodgkin / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16868486.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 34
  •  go-up   go-down


11. Ueda K, Nagayama Y, Narita K, Kusano M, Mernyei M, Kamiya M: Pancreatic involvement by non-Hodgkin's lymphoma. J Hepatobiliary Pancreat Surg; 2000;7(6):610-3
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic involvement by non-Hodgkin's lymphoma.
  • A case of pancreatic involvement by non-Hodgkin's lymphoma is presented.
  • Therefore, pancreatoduodenectomy and right hemicolectomy were performed, although a definitive preoperative diagnosis was not obtained.
  • This tumor was identified, by histopathology and immunohistochemistry, as diffuse mixed type lymphoma with a B-cell phenotype.
  • Postoperatively, the patient had severe congestive heart failure, and he died without receiving chemotherapy.
  • It is important to establish a definitive diagnosis for this disease, to remove the tumor, and to treat the patient with appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Fatal Outcome. Heart Neoplasms / radiography. Heart Neoplasms / secondary. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180896.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


12. Boni L, Benevento A, Dionigi G, Cabrini L, Dionigi R: Primary pancreatic lymphoma. Surg Endosc; 2002 Jul;16(7):1107-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic lymphoma.
  • Primary pancreatic lymphoma (PPL) is a rare form of extranodal lymphoma (less than 0.5% of pancreatic tumors) originating from the pancreatic parenchyma.
  • Histopathological examination is usually mandatory to obtain a definitive diagnosis since symptoms and radiological features are quite similar to those of other pancreatic masses.
  • Percutaneous fine-needle aspiration (FNA) of the pancreas requires experienced cytopathologists as well as advanced immunohistochemical assays to obtain a final diagnosis on a small amount of tissue.
  • Abdominal ultrasound revealed the presence of a large hyperechogenic mass, mainly located at the pancreatic head.
  • Abdominal computed tomography scan confirmed a diffuse enlargement of the head and body of the pancreas associated with lymphadenopathy along the lesser gastric curvature.
  • Multiple biopsies of the pancreatic head were taken and lymphadenectomy along the lesser curvature and the hepatic hilus was also performed.
  • The definitive histopathological examination of the pancreatic specimen revealed a primary low-grade non-Hodgkin B cell pancreatic lymphoma.
  • The postoperative course was unremarkable; the patient underwent systemic chemotherapy regime for low-grade B cell Hodgkin lymphoma and he was symptom free at 9-month follow-up.
  • [MeSH-major] Lymphoma, B-Cell / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Diabetes Mellitus, Type 1 / surgery. Diagnostic Techniques, Surgical. Humans. Laparoscopy / methods. Lymph Node Excision / methods. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11984658.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Kochi M, Fujii M, Kanamori N, Kaiga T, Takahashi T, Kobayashi M, Takayama T: Complete remission by chemotherapy in stage IE-IIE primary gastric lymphoma. Hepatogastroenterology; 2007 Jun;54(76):1285-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission by chemotherapy in stage IE-IIE primary gastric lymphoma.
  • BACKGROUND/AIMS: There are many controversies regarding the treatment for primary gastric non-Hodgkin's lymphoma (PGL).
  • We hypothesized that preoperative chemotherapy and extensive surgery would improve patient survival in the treatment of early stage patients with PGL.
  • All patients received preoperative chemotherapy, i.e.
  • Upon the completion of chemotherapy, the extensive surgery including total gastrectomy, splenectomy, cholecystectomy, and paraaortic lymphadenectomy were performed.
  • The response rates of preoperative chemotherapy and overall survival were analyzed.
  • In all patients, microscopic examinations did not reveal residual lymphoma cells in the resected stomach or lymph nodes.
  • Chemotherapy-related preoperative complications such as perforation or intestinal bleeding did not occur in any of the cases.
  • Postoperative complications developed in 30% (3/10) of patients and consisted of 2 pancreatic fistulas, 3 intra-abdominal abscesses, and 1 anastomotic leak.
  • CONCLUSIONS: Primary chemotherapy alone without surgery may produce complete remission in Stage IE-IIE PGL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Bleomycin / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Preoperative Care. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629090.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; MACOP-B protocol
  •  go-up   go-down


14. Merkle EM, Bender GN, Brambs HJ: Imaging findings in pancreatic lymphoma: differential aspects. AJR Am J Roentgenol; 2000 Mar;174(3):671-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging findings in pancreatic lymphoma: differential aspects.
  • Lymphoma does not require surgical staging or a palliative Whipple's procedure before chemotherapy or radiation therapy.
  • A better overall prognosis with nonsurgical treatment is additional impetus to search for secondary signs of primary pancreatic lymphoma.
  • In patients with primary pancreatic lymphoma, no marked pancreatic ductal dilatation is present even with ductal invasion.
  • Adenocarcinoma commonly dilates the more distal pancreatic duct when more proximal ductal invasion has taken place.
  • Clinical and imaging findings are otherwise not specific in the differentiation of pancreatic lymphoma and pancreatic cancer, but a bulky homogeneous tumoral mass without alteration of Wirsung's duct or the peripancreatic vessels should suggest the diagnosis.
  • In patients with diffuse infiltration of the pancreatic gland without clinical signs of pancreatitis, the radiologist should be alert to the possibility of pancreatic lymphoma.
  • [MeSH-major] Diagnostic Imaging. Lymphoma, Non-Hodgkin / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10701607.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


15. Lossos I, Craig MD, Tallman MS, Boccia RV, Conkling PR, Becerra C, Komarnitsky PB, Hamilton BL, Lewis J, Miller WH: Novel organic arsenic molecule darinaparsin: Development of IV and oral forms. J Clin Oncol; 2009 May 20;27(15_suppl):8501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Darinaparsin i.v. activity in lymphoma is being evaluated in a phase II study.
  • METHODS: Phase II trial is being conducted in patients diagnosed with advanced lymphomas who had ≥ 1 prior therapy.
  • RESULTS: The phase II study has accrued 28 lymphoma patients (21 non-Hodgkin's, 7 Hodgkin's); median age at baseline 61 years, ECOG ≤2, median number of prior therapies 3.
  • Of these, 1 subject (PTCL) has achieved a complete response, 3 - partial responses (2 marginal zone, 1 Hodgkin's), and 4 stable disease (2 PTCL, 1 DLBCL, 1 Hodgkin's).
  • A total of 63 cycles of darinaparsin have been administered to subjects with lymphoma. No Gr.
  • 3 or higher drug-related AEs were reported.
  • Two SAEs were considered possibly drug-related (fall; neutropenic fever).
  • Phase I studies accrued 35 patients; median age at baseline 58 years, ECOG ≤2, median number of prior therapies 3.
  • Predominant tumor types include: colorectal (17), pancreatic (3), NHL (3).
  • Drug-related AEs include nausea/vomiting, fatigue, decreased appetite/anorexia.
  • CONCLUSIONS: Darinaparsin is active in heavily pretreated patients with advanced lymphoma and has been very well tolerated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960853.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kurosawa H, Matsunaga T, Shimaoka H, Sato Y, Kuwashima S, Sugita K, Hagane K, Eguchi M: Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction. J Pediatr Hematol Oncol; 2002 May;24(4):310-2
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction.
  • Large gastric folds in adults are seen in many benign and malignant conditions, but they are rare in children with malignant diseases such as non-Hodgkin lymphoma.
  • The authors report a patient with non-Hodgkin lymphoma who had large gastric folds and jaundice as the initial symptoms.
  • Magnetic resonance imaging showed a typical diffuse infiltrating type of pancreatic lymphoma.
  • Because complete bilateral lower limb paralysis developed as a result of the epidural soft tissue mass, laminectomy and tumor resection were performed and a diagnosis of disseminated Burkitt lymphoma was established.
  • After completing 6 months of chemotherapy, the patient has been disease-free without neurologic complications for 2.5 years.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cholestasis / diagnosis. Gastric Mucosa / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11972102.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Hauksson IT, Guðbjartsson T, Hrafnkelsson J, Sigurðsson F, Magnússon J: [Primary pancreatic lymphoma causing obstructive jaundice in a 71 year old man. A case report and review of the literature.]. Laeknabladid; 2002 Mar;88(3):189-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pancreatic lymphoma causing obstructive jaundice in a 71 year old man. A case report and review of the literature.].
  • Primary lymphoma of the pancreas is a very rare disease.
  • They are difficult to diagnose and have good prognosis, due to their sensitivity to chemotherapy and radiation.
  • As compared to the more common pancreatic adenocarcinomas which usually have bad prognosis.
  • We report a case of primary pancreatic non-Hodgkin s lymphoma diagnosed in a 71 year old icteric man.
  • Chemotherapy and radiation therapy was started after relieving the jaundice with a PTC-introduced stent through the pancreatic part of the choledochus.
  • This is the first reported case of pancreatic lymphoma in Iceland.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940648.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


18. Levy MJ, Wiersema MJ: Endoscopic removal of a biliary Wallstent with a suture-cutting device in a patient with primary pancreatic lymphoma. Endoscopy; 2002 Oct;34(10):835-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic removal of a biliary Wallstent with a suture-cutting device in a patient with primary pancreatic lymphoma.
  • This report describes the case of a 74-year-old woman who had previously had a metal stent placed to relieve jaundice resulting from a pancreatic head tumor, suspected to be adenocarcinoma.
  • The tumor was subsequently found to be a non-Hodgkin's large-cell lymphoma, which had shown a rapid response to chemotherapy without tumor recurrence in over 3 years since the diagnosis.
  • [MeSH-major] Device Removal. Endoscopy / methods. Jaundice / therapy. Lymphoma, Non-Hodgkin / therapy. Pancreatic Neoplasms / therapy. Stents

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12244508.001).
  • [ISSN] 0013-726X
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Metals
  •  go-up   go-down


19. Urahashi T, Miura O, Otawa R, Kawano T, Matsusaki K, Toda T, Minamisono Y, Nagasaki S: En bloc resection for primary non-Hodgkin's lymphoma of the descending colon with massive extension into the neighboring organs. Hepatogastroenterology; 2007 Jan-Feb;54(73):144-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc resection for primary non-Hodgkin's lymphoma of the descending colon with massive extension into the neighboring organs.
  • A 79-year-old female who was surgically treated and received adjuvant chemotherapy for primary non-Hodgkin's lymphoma of the descending colon with massive extension into the pancreatic tail, spleen, and left kidney is herein reported.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Colonic Diseases / etiology. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Obstruction / etiology. Lymphocytes / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419249.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Logan RM, Gibson RJ, Sonis ST, Keefe DM: Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol; 2007 Apr;43(4):395-401
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy.
  • Oral mucositis is a serious and debilitating side effect of cancer treatment.
  • Greater understanding of the pathobiology of mucositis has recently led to the advent of targeted treatments for specific patient populations; however the treatment for mucositis remains palliative for most patients.
  • In this study, 20 patients undergoing cytotoxic chemotherapy had oral mucosal biopsies taken prior to and following administration of cytotoxic chemotherapy.
  • The results from this preliminary study demonstrated statistically significant increased oral mucosal staining for NF-kappaB and COX-2 following cytotoxic chemotherapy and provide further support for the role of NF-kappaB and COX-2 in the pathogenesis of mucositis.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cyclooxygenase 2 / biosynthesis. Mouth Mucosa / drug effects. NF-kappa B / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Female. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Humans. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pilot Projects

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979925.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NF-kappa B; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


21. Dote H, Ohta K, Nishimura R, Teramoto N, Asagi A, Nadano S, Hamada M, Yoshida I, Kobatake T, Nozaki I, Kubo Y, Tanada M, Kurita A, Takashima S: Primary extranodal non-Hodgkin's lymphoma of the common bile duct manifesting as obstructive jaundice: report of a case. Surg Today; 2009;39(5):448-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extranodal non-Hodgkin's lymphoma of the common bile duct manifesting as obstructive jaundice: report of a case.
  • Primary non-Hodgkin's lymphoma (NHL) of the common bile duct (CBD) manifesting as obstructive jaundice is extremely rare: to our knowledge, only 22 cases of primary NHL arising from the CBD have been reported.
  • Abdominal sonography, positron emission tomography, and computed tomography showed a mass with abnormal 18-fluorodeoxyglucose uptake in pancreatic head.
  • We performed pancreaticoduodenectomy for a presumptive diagnosis of pancreatic head carcinoma or cholangiocarcinoma of the CBD.
  • However, the histological diagnosis was a primary, diffuse, large B-cell lymphoma of the CBD.
  • He received three courses of combination chemotherapy, including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
  • In summary, primary NHL of the CBD, despite its rarity, should be considered in the differential diagnosis of obstructive jaundice.
  • An accurate histopathologic diagnosis and complete surgical resection, followed by combination chemotherapy plus rituximab may be effective.
  • [MeSH-major] Common Bile Duct / pathology. Common Bile Duct Neoplasms / diagnosis. Jaundice, Obstructive / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2007;37(7):608-11 [17593484.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2218-22 [7127262.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jun;182(6):1608-9 [15150028.001]
  • [Cites] Hepatogastroenterology. 1991 Jun;38(3):235-8 [1937362.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(2):196-9 [18392714.001]
  • [Cites] Surgery. 2003 Sep;134(3):496-500 [14555939.001]
  • [Cites] J Gastroenterol. 2004 Jul;39(7):692-6 [15293142.001]
  • [Cites] Surg Today. 2008;38(1):76-80 [18085371.001]
  • [Cites] Am J Gastroenterol. 1997 Sep;92(9):1543-6 [9317083.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):285-92 [14579295.001]
  • (PMID = 19408087.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Rocha Lima CM, Urbanic JJ, Lal A, Kneuper-Hall R, Brunson CY, Green MR: Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol; 2001 Jun;28(3 Suppl 10):34-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
  • Non-platinum combinations including gemcitabine and irinotecan (Gemzar; Eli Lilly and Company, Indianapolis, IN) for the management of a variety of malignancies have started to emerge.
  • Preclinical data suggests synergy for the two drugs when used in combination.
  • A phase I trial has defined a well-tolerated combination regimen using both drugs on a day-1, -8 schedule every 3 weeks.
  • Phase II data suggest activity for the combination in pancreatic cancer, and a phase III trial of the two-drug combination versus gemcitabine alone is underway in previously untreated pancreatic cancer patients.
  • Other phase II trials evaluating the impact of this combination on a variety of other tumors, such as non-small cell lung, small cell lung, breast, colorectal, and non-Hodgkin's lymphoma, are either forthcoming or in progress.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Deoxycytidine / administration & dosage
  • [MeSH-minor] Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / drug therapy. Clinical Trials as Topic. Colorectal Neoplasms / drug therapy. Hematologic Neoplasms / drug therapy. Humans. Lung Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11510032.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0H43101T0J / irinotecan; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 70
  •  go-up   go-down


23. Genvresse I, Lange C, Schanz J, Schweigert M, Harder H, Possinger K, Späth-Schwalbe E: Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anticancer Drugs; 2001 Apr;12(4):345-9
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
  • We evaluated 268 consecutive administrations of amifostine (119 in group I and 149 in group II, respectively), given i.v. at a dose of 740 mg/m(2) just before platinum-, taxol- or cyclophosphamide-based chemotherapy.
  • The amifostine infusion was interrupted 16 times in group I and 8 times in group II, respectively, mainly due to hypotension, but could be restarted after a few minutes in all patients except for three cases in group I.
  • [MeSH-major] Amifostine / administration & dosage. Amifostine / toxicity. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hypocalcemia / epidemiology. Lymphoma, Non-Hodgkin / drug therapy. Nausea / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Antihypertensive Agents / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Doxorubicin / administration & dosage. Epirubicin / administration & dosage. Esophageal Neoplasms / drug therapy. Female. Fluorouracil / administration & dosage. Humans. Hypertension / complications. Hypotension / chemically induced. Infusions, Intravenous. Lung Neoplasms / drug therapy. Male. Middle Aged. Paclitaxel / administration & dosage. Pancreatic Neoplasms / drug therapy. Platinum / administration & dosage. Prednisone / administration & dosage. Premedication. Retrospective Studies. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11335791.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 49DFR088MY / Platinum; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


24. Braschoss S, Hirsch B, Dübel S, Stein H, Dürkop H: New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo. Leuk Lymphoma; 2007 Jun;48(6):1179-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo.
  • Although the therapy of Hodgkin lymphoma and anaplastic large cell lymphoma has been considerably improved during the last decades, high therapeutic toxicity, relapses, secondary tumors, and primary treatment failure(s) occur.
  • We constructed an immunotoxin composed of a single chain variable fragment of a CD30 antibody fused to the human pancreatic ribonuclease, showing CD30-specific binding and ribonucleolytic activity resistant to the inhibitor RNasin.
  • [MeSH-major] Antigens, CD30 / immunology. Cytotoxins / pharmacology. Immunotoxins / pharmacology. Ribonuclease, Pancreatic / immunology
  • [MeSH-minor] Animals. Antibody Specificity. Cell Line. Cell Proliferation / drug effects. Drosophila melanogaster. Female. Humans. Mice. Mice, Inbred BALB C. Neoplasm Transplantation / pathology. Protein Binding. Recombinant Fusion Proteins / immunology. Recombinant Fusion Proteins / isolation & purification. Recombinant Fusion Proteins / metabolism. Transplantation, Isogeneic / pathology. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Jun;48(6):1067-9 [17577767.001]
  • (PMID = 17577782.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Cytotoxins; 0 / Immunotoxins; 0 / Recombinant Fusion Proteins; EC 3.1.27.5 / Ribonuclease, Pancreatic
  •  go-up   go-down


25. Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, Raju U: Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study. Anticancer Res; 2009 Nov;29(11):4409-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.
  • BACKGROUND: Imexon is an aziridine-containing small pro-oxidant molecule with promising antitumor activity in myeloma, lymphoma and lung and pancreatic cancer.
  • The present study examined the effects of imexon on H9 and Raji lymphoma cell lines in vitro when given in combination with ionizing radiation.
  • MATERIALS AND METHODS: H9 and Raji lymphoma cells were grown in culture and exposed to imexon, radiation, or both.
  • CONCLUSION: In conclusion, imexon efficiently augmented lymphoma cell radiosensitivity independently of glutathione and the underlying mechanisms include induction of apoptosis and cell cycle redistribution.
  • [MeSH-major] Hexanones / pharmacology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / radiotherapy. Radiation-Sensitizing Agents / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Combined Modality Therapy. Humans. Oxidation-Reduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032386.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Hexanones; 0 / Radiation-Sensitizing Agents; 59643-91-3 / 4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
  •  go-up   go-down


26. Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, Barth S, Engert A: Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res; 2001 Dec 15;61(24):8737-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
  • Because these foreign proteins are highly immunogenic in humans, we have developed a new CD30 ligand-based fusion toxin (Ang-CD30L) using the human RNase angiogenin.
  • The characteristics of the recombinant protein were assessed by ELISA, flow cytometry, and toxicity assays showing specific activity against CD30(+) Hodgkin-derived cells.
  • This is the first report on the specific cytotoxicity of a recombinant completely human fusion toxin with possibly largely reduced immunogenicity for the treatment of CD30-positive malignancies.
  • [MeSH-major] Antigens, CD30 / metabolism. Hodgkin Disease / drug therapy. Immunotoxins / pharmacology. Membrane Glycoproteins / pharmacology. Recombinant Fusion Proteins / pharmacology. Ribonuclease, Pancreatic / pharmacology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11751393.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CD30 Ligand; 0 / Immunotoxins; 0 / Membrane Glycoproteins; 0 / Recombinant Fusion Proteins; 0 / TNFSF8 protein, human; EC 3.1.- / Ribonucleases; EC 3.1.27.- / angiogenin; EC 3.1.27.5 / Ribonuclease, Pancreatic
  •  go-up   go-down


27. Snady H: Interventional endoscopy, neoadjuvant therapy and the gastroenterologist. Hematol Oncol Clin North Am; 2002 Feb;16(1):53-79
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventional endoscopy, neoadjuvant therapy and the gastroenterologist.
  • With current treatment, survival of greater than 1 year should be anticipated for many patients with pancreatic cancer.
  • Obstructive jaundice is managed successfully with endoscopic placement of a plastic stent early in the evaluation of a patient with suspected regional pancreatic cancer, and a metal wall stent is reserved for patients with known 1997 AJCC stage IVB carcinoma or nonoperative patients.
  • Relief of biliary obstruction allows improvement in liver function and more time to evaluate tumor stage accurately to determine initial treatment (see Fig. 1).
  • A cost-effective algorithm to determine accurate stage and treatment can start with the size of the mass on initial imaging studies.
  • EUS-guided FNA represents a significant improvement over CT scan-guided FNA to make a tissue diagnosis.
  • Small pancreatic masses that would be resected regardless of whether an FNA is positive or negative require only an EUS evaluation to establish an early resectable stage.
  • Tumors reliably staged as unresectable by nonoperative imaging methods including EUS are treated with chemotherapy with or without concurrent radiotherapy because median survival of these patients is 2 years in some series.
  • For chronic pain or gastric outlet obstruction not responding or treatable by chemoradiotherapy, endoscopically guided celiac plexus nerve block and stenting improve the quality of life for patients with pancreatic cancer.
  • A team approach is required to achieve the objectives of improved quality of life, prolonged survival, and possible cure for pancreatic cancer.
  • Rather than reliance on any single standard, clinical judgment and communication among the team are paramount to providing optimal care for patients with a pancreatic neoplasm.
  • [MeSH-major] Adenocarcinoma / therapy. Endoscopy. Endoscopy, Gastrointestinal. Endosonography. Neoadjuvant Therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Ampulla of Vater / surgery. Antineoplastic Agents / therapeutic use. Autonomic Nerve Block / methods. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / therapy. Chemotherapy, Adjuvant. Cholangiopancreatography, Endoscopic Retrograde. Cholestasis / etiology. Cholestasis / therapy. Combined Modality Therapy. Common Bile Duct Neoplasms / surgery. Diagnostic Imaging / methods. Gastric Outlet Obstruction / surgery. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Staging / methods. Pain Management. Palliative Care. Pancreatic Cyst / therapy. Prognosis. Radiotherapy, Adjuvant. Stents

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063829.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 115
  •  go-up   go-down


28. Fonsatti E, Maio M, Altomonte M, Hersey P: Biology and clinical applications of CD40 in cancer treatment. Semin Oncol; 2010 Oct;37(5):517-23
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology and clinical applications of CD40 in cancer treatment.
  • Engagement of surface CD40 mediates different effects depending on cell type and microenvironment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD40 / antagonists & inhibitors. Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / immunology. Melanoma / drug therapy. Melanoma / immunology. Molecular Targeted Therapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / immunology. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074067.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD40; 0 / Antineoplastic Agents
  •  go-up   go-down


29. Morré DJ, Hostetler B, Weston N, Kim C, Morré DM: Cancer type-specific tNOX isoforms: A putative family of redox protein splice variants with cancer diagnostic and prognostic potential. Biofactors; 2008;34(3):201-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer type-specific tNOX isoforms: A putative family of redox protein splice variants with cancer diagnostic and prognostic potential.
  • A proteomics approach with detection on western blots using an S-peptide tagged pan-tNOX (ENOX2) recombinant (scFv) antibody followed by alkaline phosphatase-linked anti S has revealed a family of more than 20 ENOX2 isoforms of varying molecular weights (34 to 94 kDa) and mostly of low isoelectric points (4.6 +/- 0.7) based on serum analysis.
  • Different isoforms characterize cancers of different tissue origins indicative of both cancer presence and tissue site of origin.
  • ENOX2 proteins are cancer-associated and differ from constitutive (CNOX or ENOX1) proteins primarily by the absence of a drug binding site to which the cancer-specific scFv is directed.
  • The tNOX isoform technology is under development as a clinical aid to identify unknown or uncertain primary cancers, evaluation of metastatic spread in post surgery patients, monitoring remission following cessation of therapy and for early diagnosis in at-risk populations.
  • [MeSH-minor] Blotting, Western. Breast Neoplasms / metabolism. Colonic Neoplasms / metabolism. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Lung Neoplasms / metabolism. Lymphoma, Non-Hodgkin / metabolism. Male. Melanoma / metabolism. Ovarian Neoplasms / metabolism. Pancreatic Neoplasms / mortality. Prostatic Neoplasms / metabolism. Uterine Cervical Neoplasms

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734121.001).
  • [ISSN] 1872-8081
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Protein Isoforms; EC 1.6.- / NADH, NADPH Oxidoreductases; EC 1.6.- / tumor-associated NADH oxidase
  •  go-up   go-down






Advertisement